We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.
- Authors
Shah, Jatin; Wang, Wenquan; Harrough, V Douglas; Saville, Wayne; Meredith, Ruby; Shen, Sui; Mueh, John; Lister, John; Jasthy, Sri; Maggass, Gregory; McKay, Charles; Krumdieck, Richard; Tharp, Morgan; Winter, Christine; Gregory, Stephanie; Buchholz, William; Awasthi, Sanjay; Jacobs, Samuel; Chung, Harold; Egner, James; Lobuglio, Albert F; Forero, Andres
- Abstract
There is no data on safety and efficacy of a second course of ibritumomab tiuxetan. In this work, data on patients with B-cell NHL who were treated with two courses of ibritumomab tiuxetan were analyzed. Eighteen such patients were analyzed (age: 58 years, 48 - 91), with a median of four prior regimens (1 - 7), stem cell transplantation (n = 5), and radiation therapy (n = 6). After the first course, G3/4 neutropenia and thrombocytopenia was 35% and 41%; overall response rate (ORR) was 89%; time between courses was 16.6 months (6.0 - 42.7). After the second course, the incidence of G3/4 neutropenia and thrombocytopenia was 28% and 44%; and ORR 77%. There were no infectious or bleeding complications, secondary myelodysplastic syndromes, or leukemias. Retreatment with the ibritumomab tiuxetan regimen was well tolerated, with a safety profile similar to that of the first course. To conclude, patients who benefited from the first course of ibritumomab tiuxetan can benefit from retreatment.
- Publication
Leukemia & lymphoma, 2007, Vol 48, Issue 9, p1736
- ISSN
1042-8194
- Publication type
Journal Article
- DOI
10.1080/10428190701528517